The use of Revlimid (lenalidomide) as a maintenance therapy for adult patients with newly diagnosed multiple myeloma who underwent autologous stem cell transplant (ASCT)…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
The use of Revlimid (lenalidomide) as a maintenance therapy for adult patients with newly diagnosed multiple myeloma who underwent autologous stem cell transplant (ASCT)…
Combination treatment with Velcade (bortezomib) and Thalomid (thalidomide) may significantly improve survival of multiple myeloma patients who received a stem cell transplant, according to recent…
Cellectar Biosciences has been granted a U.S. patent for the method of use for the compounds CLR 131 and CLR 125 in the treatment of…
Patients with bone metastasis due to multiple myeloma, breast or prostate cancer, who received zoledronic acid every 12 weeks for two years, did not have increased risk of skeletal-related events…
The Kerry and Simone Vickar Family Foundation has committed $2 million to establish an endowed chair in their name at the Levine Cancer…
MYELOMA
A new type of dendritic cell-based immunotherapy triggered an immune response in the majority of patients in a small Phase 1 trial (NCT02248402) of…
Don't have an account?
|
Already have an account?
Create your account by filling in the information below:
By creating an account, you are agreeing to the Privacy Policy and Terms of Service.